Dr. Pankit J. Vachhani, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 148
Licensed in Alabama since 2018, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AL license 36841 (first issued 2018; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 148
- Services billed
- 486
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 246 | 39 |
| Established patient office or other outpatient visit, 30-39 minutes | 113 | 64 |
| Established patient office or other outpatient visit, 40-54 minutes | 33 | 23 |
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
| Hospital discharge day management, 30 minutes or less | 24 | 18 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 23 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 165 |
| Hydroxyurea Other prescribers in Birmingham, AL | 107 |
| Acyclovir Other prescribers in Birmingham, AL | 90 |
| Sprycel (dasatinib) | 84 |
| Oxycodone Hcl Other prescribers in Birmingham, AL | 64 |
| Vonjo (pacritinib citrate) | 41 |
| Bosulif (bosutinib) | 39 |
| Venclexta (venetoclax) | 38 |
| Ayvakit (avapritinib) | 38 |
| Eliquis (apixaban) Other prescribers in Birmingham, AL | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 149 payments worth $168,654 in total to this clinician.
| Incyte Corporation | $51,719 |
|---|---|
| GlaxoSmithKline, LLC. | $38,348 |
| Blueprint Medicines Corporation | $20,162 |
| Takeda Pharmaceuticals U.S.A., Inc. | $14,655 |
| Pharmaessentia USA Corporation | $14,611 |
| Syndax Pharmaceuticals, Inc. | $8,625 |
| Karyopharm Therapeutics Inc. | $8,256 |
| Merck Sharp & Dohme LLC | $7,492 |
| Consulting Fee | $87,405 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $54,433 |
| Honoraria | $11,630 |
| Travel and Lodging | $10,617 |
| Food and Beverage | $4,569 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $29,600 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 28, 2025 | Consulting Fee | $11,440 |
| Pharmaessentia USA Corporation Nov 24, 2025 | Consulting Fee BESREMI · Oncology | $10,413 |
| Incyte Corporation Apr 10, 2025 | Consulting Fee | $9,590 |
| Incyte Corporation Oct 24, 2025 | Consulting Fee | $7,193 |
| Blueprint Medicines Corporation Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,056 |
| Incyte Corporation Mar 3, 2025 | Consulting Fee Jakafi · Hematology/Oncology | $6,850 |
| Blueprint Medicines Corporation Feb 26, 2025 | Honoraria | $6,776 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,760 |
| Incyte Corporation Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $5,480 |
All 78 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Dec 15, 2025 | Travel and Lodging travel to MELBOURNE, Australia | $204 |
| GlaxoSmithKline, LLC. Dec 15, 2025 | Consulting Fee | $198 |
| GlaxoSmithKline, LLC. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $29,600 |
| Incyte Corporation Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $2,055 |
| Pharmaessentia USA Corporation Nov 24, 2025 | Consulting Fee BESREMI · Oncology | $10,413 |
| Pharmaessentia USA Corporation Nov 24, 2025 | Travel and Lodging BESREMI · Oncology · travel to Chicago, IL | $492 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,760 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Travel and Lodging travel to Fairfield, NJ | $150 |
| GlaxoSmithKline, LLC. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $29.60 |
| Merck Sharp & Dohme LLC Nov 4, 2025 | Travel and Lodging ONCOLOGY · travel to Fairfield, NJ · in-kind | $385 |
| Merck Sharp & Dohme LLC Nov 4, 2025 | Travel and Lodging ONCOLOGY · travel to Fairfield, NJ · in-kind | $240 |
| Merck Sharp & Dohme LLC Nov 4, 2025 | Travel and Lodging ONCOLOGY · travel to Fairfield, NJ · in-kind | $240 |
| Merck Sharp & Dohme LLC Nov 3, 2025 | Travel and Lodging ONCOLOGY · travel to Fairfield, NJ · in-kind | $292 |
| Merck Sharp & Dohme LLC Nov 3, 2025 | Travel and Lodging ONCOLOGY · travel to Fairfield, NJ · in-kind | $182 |
| Incyte Corporation Oct 24, 2025 | Consulting Fee | $7,193 |
| Incyte Corporation Oct 24, 2025 | Travel and Lodging travel to Wilmington, DE | $764 |
| Incyte Corporation Oct 24, 2025 | Travel and Lodging travel to Wilmington, DE | $329 |
| Incyte Corporation Oct 24, 2025 | Travel and Lodging travel to Wilmington, DE | $34.00 |
| Incyte Corporation Oct 23, 2025 | Travel and Lodging travel to Wilmington, DE | $72.38 |
| Incyte Corporation Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $2,055 |
| Incyte Corporation Aug 28, 2025 | Consulting Fee | $2,740 |
| Incyte Corporation Aug 21, 2025 | Travel and Lodging travel to Charlotte, NC | $269 |
| Incyte Corporation Aug 21, 2025 | Travel and Lodging travel to Charlotte, NC | $25.50 |
| Incyte Corporation Aug 21, 2025 | Travel and Lodging travel to Charlotte, NC | $20.55 |
| Karyopharm Therapeutics Inc. Aug 6, 2025 | Honoraria XPOVIO · Oncology | $850 |
| GlaxoSmithKline, LLC. Aug 4, 2025 | Consulting Fee OJJAARA · ONCOLOGY | $400 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 30, 2025 | Consulting Fee ICLUSIG · ONCOLOGY | $1,760 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 30, 2025 | Travel and Lodging ICLUSIG · ONCOLOGY · travel to CAMBRIDGE, MA · in-kind | $556 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 30, 2025 | Travel and Lodging ICLUSIG · ONCOLOGY · travel to CAMBRIDGE, MA · in-kind | $210 |
| Incyte Corporation Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $5,480 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 28, 2025 | Consulting Fee | $11,440 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 28, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $556 |
| GlaxoSmithKline, LLC. Jul 23, 2025 | Consulting Fee | $5,075 |
| Incyte Corporation Jul 20, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to New Orleans, LA | $1,008 |
| Incyte Corporation Jul 20, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to New Orleans, LA | $269 |
| Incyte Corporation Jul 20, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to New Orleans, LA | $170 |
| Incyte Corporation Jul 20, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to New Orleans, LA | $170 |
| Incyte Corporation Jul 20, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to New Orleans, LA | $34.00 |
| Incyte Corporation Jul 20, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to New Orleans, LA | $18.83 |
| Incyte Corporation Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $2,055 |
| Syndax Pharmaceuticals, Inc. Jun 11, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,200 |
| Syndax Pharmaceuticals, Inc. Jun 11, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to MILAN, Italy | $187 |
| Syndax Pharmaceuticals, Inc. Jun 11, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to MILAN, Italy | $183 |
| Syndax Pharmaceuticals, Inc. May 30, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,200 |
| Syndax Pharmaceuticals, Inc. May 30, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL | $556 |
| Syndax Pharmaceuticals, Inc. May 30, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL · in-kind | $445 |
| Syndax Pharmaceuticals, Inc. May 30, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL | $117 |
| Syndax Pharmaceuticals, Inc. May 30, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL | $42.00 |
| Syndax Pharmaceuticals, Inc. May 30, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL | $18.02 |
| Sobi, Inc May 22, 2025 | Travel and Lodging Vonjo · Hematology/Oncology · travel to Detroit, MI | $224 |
| Incyte Corporation May 20, 2025 | Consulting Fee Jakafi · Hematology/Oncology | $1,370 |
| Incyte Corporation Apr 28, 2025 | Consulting Fee Jakafi · Hematology/Oncology | $4,110 |
| Sobi, Inc Apr 12, 2025 | Travel and Lodging Vonjo · Hematology/Oncology · travel to San Francisco, CA | $6.08 |
| Incyte Corporation Apr 10, 2025 | Consulting Fee | $9,590 |
| Incyte Corporation Apr 10, 2025 | Travel and Lodging travel to Irving, TX | $138 |
| Incyte Corporation Apr 10, 2025 | Travel and Lodging travel to Irving, TX | $41.00 |
| Incyte Corporation Apr 9, 2025 | Travel and Lodging travel to Irving, TX | $242 |
| Incyte Corporation Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) Jakafi · Hematology/Oncology | $343 |
| Blueprint Medicines Corporation Mar 14, 2025 | Honoraria AYVAKIT · Oncology / Rare Diseases | $4,004 |
| Blueprint Medicines Corporation Mar 14, 2025 | Travel and Lodging AYVAKIT · Oncology / Rare Diseases · travel to Huntsville, AL | $155 |
| Incyte Corporation Mar 3, 2025 | Consulting Fee Jakafi · Hematology/Oncology | $6,850 |
| Blueprint Medicines Corporation Feb 27, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $787 |
| Blueprint Medicines Corporation Feb 26, 2025 | Honoraria | $6,776 |
| Blueprint Medicines Corporation Feb 26, 2025 | Travel and Lodging travel to San Diego, CA | $45.31 |
| Blueprint Medicines Corporation Feb 25, 2025 | Travel and Lodging travel to San Diego, CA | $39.00 |
| Incyte Corporation Feb 11, 2025 | Consulting Fee | $3,425 |
| Karyopharm Therapeutics Inc. Feb 4, 2025 | Consulting Fee XPOVIO · Oncology | $1,630 |
| AbbVie Inc. Jan 30, 2025 | Consulting Fee | $1,875 |
| AbbVie Inc. Jan 30, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $72.00 |
| AbbVie Inc. Jan 30, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $17.62 |
| Blueprint Medicines Corporation Jan 27, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,056 |
| Blueprint Medicines Corporation Jan 23, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $600 |
| AbbVie Inc. Jan 15, 2025 | Travel and Lodging VENCLEXTA · ONCOLOGY · travel to SAN DIEGO, CA · in-kind | $10.09 |
| AbbVie Inc. Jan 13, 2025 | Consulting Fee | $1,500 |
| Karyopharm Therapeutics Inc. Jan 10, 2025 | Consulting Fee XPOVIO · Oncology | $4,890 |
| Karyopharm Therapeutics Inc. Jan 10, 2025 | Consulting Fee XPOVIO · Oncology | $815 |
| Pharmaessentia USA Corporation Jan 9, 2025 | Consulting Fee BESREMI · Oncology | $3,332 |
| GlaxoSmithKline, LLC. Jan 9, 2025 | Consulting Fee OJJAARA · ONCOLOGY | $2,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 14 companies. The companies reported $2,529,071 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Novartis Pharmaceuticals Corporation - A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis
Karyopharm Therapeutics Inc. - A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis
Incyte Corporation - A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Sumitomo Pharma America, Inc. · Recruiting · NCT04176198 - Study name not reported
Pharmaessentia USA Corporation - (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation · Active, not recruiting · NCT03731260 - PAC203/PAC303
Sobi, Inc - A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Takeda Pharmaceuticals U.S.A., Inc. · Active, not recruiting · NCT03589326 - A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)
Ionis Pharmaceuticals, Inc. - A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.